Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, Fricke S, Franz P, Heyn S, Kubasch AS, Baber R, Weidner H, Wang SY, Bach E, Hoffmann S, Ussmann J, Kirchberg J, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Reiche K, Köhl U, Platzbecker U, Vucinic V, Merz M. Fischer L, et al. Among authors: heyn s. Leukemia. 2024 Feb;38(2):372-382. doi: 10.1038/s41375-023-02129-y. Epub 2024 Jan 6. Leukemia. 2024. PMID: 38184754 Free PMC article.
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia.
Hebenstreit K, Iacobelli S, Leiblein S, Eisfeld AK, Pfrepper C, Heyn S, Vucinic V, Franke GN, Krahl R, Fricke S, Becker C, Pönisch W, Behre G, Niederwieser D, Lange T. Hebenstreit K, et al. Among authors: heyn s. Leuk Lymphoma. 2014 Jun;55(6):1274-80. doi: 10.3109/10428194.2013.836598. Epub 2013 Oct 3. Leuk Lymphoma. 2014. PMID: 23964650
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Pönisch W, Moll B, Bourgeois M, Andrea M, Schliwa T, Heyn S, Schmalfeld M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Egert M, Stiegler R, Krahl R, Remane Y, Bachmann A, Lindner T, Weidhase L, Petros S, Fricke S, Vucinic V, Al Ali H, Niederwieser D. Pönisch W, et al. Among authors: heyn s. J Cancer Res Clin Oncol. 2013 Nov;139(11):1937-46. doi: 10.1007/s00432-013-1513-2. Epub 2013 Sep 18. J Cancer Res Clin Oncol. 2013. PMID: 24046251
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D. Poenisch W, et al. Among authors: heyn s. J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22. doi: 10.1007/s00432-015-1984-4. Epub 2015 May 15. J Cancer Res Clin Oncol. 2015. PMID: 25976868
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Pönisch W. Tessenow H, et al. Among authors: heyn s. J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-2058. doi: 10.1007/s00432-017-2439-x. Epub 2017 May 22. J Cancer Res Clin Oncol. 2017. PMID: 28534173
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Beck J, Schwarzer A, Gläser D, Mügge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Pönisch W. Beck J, et al. Among authors: heyn s. J Cancer Res Clin Oncol. 2017 Dec;143(12):2545-2553. doi: 10.1007/s00432-017-2504-5. Epub 2017 Aug 21. J Cancer Res Clin Oncol. 2017. PMID: 28828689 Clinical Trial.
Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report.
Kurch L, Georgi TW, Monecke A, Seehofer D, Borte G, Sabri O, Kluge R, Heyn S, Pierer M, Platzbecker U, Kayser S. Kurch L, et al. Among authors: heyn s. Front Oncol. 2022 Jan 18;11:798757. doi: 10.3389/fonc.2021.798757. eCollection 2021. Front Oncol. 2022. PMID: 35117998 Free PMC article.
Analysis of stem cell collections in adult patients with Ewing sarcoma.
Franke GN, Pfannes R, Heyn S, Brückner M, Rieprecht S, Bach E, Remane Y, Leiblein S, Pönisch W, Niederwieser D, Schwind S, Platzbecker U, Jentzsch M, Vucinic V. Franke GN, et al. Among authors: heyn s. Transfusion. 2022 Aug;62(8):1612-1618. doi: 10.1111/trf.17013. Epub 2022 Jul 8. Transfusion. 2022. PMID: 35801531
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
Wang SY, Holzhey T, Heyn S, Zehrfeld T, Fricke S, Hoffmann FA, Becker C, Braunert L, Edelmann T, Paulenz I, Hitzschke M, Flade F, Schwarzer A, Fenchel K, Franke GN, Vucinic V, Jentzsch M, Schwind S, Hell S, Backhaus D, Lange T, Niederwieser D, Scholz M, Platzbecker U, Pönisch W. Wang SY, et al. Among authors: heyn s. J Cancer Res Clin Oncol. 2023 Jul;149(7):3739-3752. doi: 10.1007/s00432-022-04184-x. Epub 2022 Aug 20. J Cancer Res Clin Oncol. 2023. PMID: 35987926 Free PMC article.
45 results